Skip to main content
Top
Published in: Tumor Biology 11/2014

01-11-2014 | Research Article

Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization

Authors: Yue Wei Zhang, Jin Ao, Ying Liu, Ming Xi Qiao, Xue Ling Yang, Shun Xiong Tang, Chuang Li, Ke Xu

Published in: Tumor Biology | Issue 11/2014

Login to get access

Abstract

The objective of this study is to investigate pharmacokinetics of gelatin sponge microparticles (GSMs) combined with epirubicin in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization (TACE). Eighteen successful models of VX2 in New Zealand white rabbits was established, which were divided into three groups randomly: HAI group (n = 6), the epirubicin solution (epirubicin 10 mg mixed with saline 10 ml into the hepatic artery); GSMs-TACE group (n = 6), GSMs (20 mg) mixed with epirubicin solution (1 mg/ml); c-TACE group (n = 6), epirubicin (10 mg) mixed with lipiodol (10 ml). Each rabbit was administrated epirubicin at dose adjusted for a 1 mg/kg. Samples were collected from femoral vein at 5, 10, 20, 30, 40, 60, 90, and 120 min after therapy after 120 min; rabbit was killed, and tumor and peritumoral normal liver tissue was cised. Epirubicin concentrations in plasma and tumor were measured. The epirubicin concentration in plasma was significantly lower in GSMs-TACE group than in HAI group. C max in there groups after administration was 28.77 ± 7.15 μg/ml in c-TACE group, 83.84 ± 32.28 μg/ml in GSMs-TACE group, and 238.46 ± 23.44 μg/ml in HAI group at 5 min, respectively. The epirubicin concentration in tumor tissue was 53.06 ± 16.9 μg/g in c-TACE group, 44.49 ± 16.80 μg/g in the GSMs-TACE group, and 18.32 ± 8.30 μg/g in HAI group, respectively. Epirubicin concentration of GSMs-TACE group was significantly higher than that of HAI group (P < 0.05). The area under the curve (AUC) at 0–120 min in c-TACE, GSMs-TACE, and HAI groups were 1,815 ± 889.88, 3,416 ± 799.90, and 11,899 ± 2,717.17 μg min/ml, respectively. The AUC was lower in GSMs-TACE group than in HAI group (P < 0.05). Compared with HAI, GSMs-TACE has higher epirubicin concentrations in tumor and lower concentrations in plasma. The results show that GSMs-TACE has a feature of slow drug release—it may be one of the mechanisms of GSMs-TACE for HCC.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. .v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. 2013. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. .v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. 2013.
3.
go back to reference Kruskal JB, Hlatky L, Hahnfeldt P, Teramoto K, Stokes KR, Clouse ME. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol. 1993;4:741–8.PubMedCrossRef Kruskal JB, Hlatky L, Hahnfeldt P, Teramoto K, Stokes KR, Clouse ME. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol. 1993;4:741–8.PubMedCrossRef
4.
go back to reference Konno T, Maeda H, Iwai K, Tashiro S, Maki S, Morinaga T, et al. Effect of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Chn Oncol. 1983;19:1058–65. Konno T, Maeda H, Iwai K, Tashiro S, Maki S, Morinaga T, et al. Effect of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Chn Oncol. 1983;19:1058–65.
5.
go back to reference Nakamura H, Tanaka T, Hori S, Yoshioka H, Kuroda C, Okamura J, et al. Transcatheter embolization of hepatocellular carcinoma: assessment of efficacy in cases of resection following embolization. Radiology. 1983;147:401–5.PubMedCrossRef Nakamura H, Tanaka T, Hori S, Yoshioka H, Kuroda C, Okamura J, et al. Transcatheter embolization of hepatocellular carcinoma: assessment of efficacy in cases of resection following embolization. Radiology. 1983;147:401–5.PubMedCrossRef
6.
go back to reference Raoul JL, Heresbach D, Bretagne JF, Ferrer DB, Duvauferrier R, Bourguet P, et al. Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer. 1992;70:585–90.PubMedCrossRef Raoul JL, Heresbach D, Bretagne JF, Ferrer DB, Duvauferrier R, Bourguet P, et al. Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer. 1992;70:585–90.PubMedCrossRef
7.
go back to reference Kerr DJ. Microparticulate drug delivery systems as an adjunct to cancer treatment. Cancer Drug Deliv. 1987;4:55–61.PubMedCrossRef Kerr DJ. Microparticulate drug delivery systems as an adjunct to cancer treatment. Cancer Drug Deliv. 1987;4:55–61.PubMedCrossRef
8.
go back to reference Lewis AL, Gonzalez MV, Lloyd AW, Hall B, Tang Y, Willis SL, et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol. 2006;17:335–42.PubMedCrossRef Lewis AL, Gonzalez MV, Lloyd AW, Hall B, Tang Y, Willis SL, et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol. 2006;17:335–42.PubMedCrossRef
9.
go back to reference Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474–81.PubMedCrossRef Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474–81.PubMedCrossRef
10.
go back to reference Li C, Zhang Y, Zhou J, Zhao G, Tang S. Therapeutic effect and tolerability of gelatin sponge particle-mediated chemoembolization for colorectal liver metastases: a retrospective study. World J Surg Oncol. 2013;11:222.PubMedCentralPubMedCrossRef Li C, Zhang Y, Zhou J, Zhao G, Tang S. Therapeutic effect and tolerability of gelatin sponge particle-mediated chemoembolization for colorectal liver metastases: a retrospective study. World J Surg Oncol. 2013;11:222.PubMedCentralPubMedCrossRef
11.
go back to reference Zhang YW, Liu Y. Transcatheter arterial chemoembolization of hepatocellular carcinoma with 350 ~ 560 μm Gelatin sponge particles: efficacy, tumour response and survival. Chin J Hepatol. 2013;21:637–8. Zhang YW, Liu Y. Transcatheter arterial chemoembolization of hepatocellular carcinoma with 350 ~ 560 μm Gelatin sponge particles: efficacy, tumour response and survival. Chin J Hepatol. 2013;21:637–8.
12.
go back to reference Zhou J, Zhang Y, Zhao G, Liu Y, Li C, Tang S, et al. The preliminary study of recombinant adenovirus p53 combined with transarterial embolization with particles for advanced hepatocellular carcinoma. Natl Med J Chin. 2014;94(9):660–3. Zhou J, Zhang Y, Zhao G, Liu Y, Li C, Tang S, et al. The preliminary study of recombinant adenovirus p53 combined with transarterial embolization with particles for advanced hepatocellular carcinoma. Natl Med J Chin. 2014;94(9):660–3.
13.
go back to reference Tabata Y, Ikada Y. Synthesis of gelatin particles containing interferon. Pharm Res. 1989;6:422–7.PubMedCrossRef Tabata Y, Ikada Y. Synthesis of gelatin particles containing interferon. Pharm Res. 1989;6:422–7.PubMedCrossRef
14.
go back to reference Konishi M, Tabata Y, Kariya M, Hosseinkhani H, Suzuki A, Fukuhara K, et al. In vivo anti-tumor effect of dual release of cisplatin and adriamycin from biodegradable gelatin hydrogel. J Control Release. 2005;103:7–19.PubMedCrossRef Konishi M, Tabata Y, Kariya M, Hosseinkhani H, Suzuki A, Fukuhara K, et al. In vivo anti-tumor effect of dual release of cisplatin and adriamycin from biodegradable gelatin hydrogel. J Control Release. 2005;103:7–19.PubMedCrossRef
15.
go back to reference Ni Y, Wang H, Chen F, Li J, DeKeyzer F, Feng Y, et al. Tumor models and specific contrast agents for small animal imaging in oncology[J]. Methods. 2009;48:125–38.PubMedCrossRef Ni Y, Wang H, Chen F, Li J, DeKeyzer F, Feng Y, et al. Tumor models and specific contrast agents for small animal imaging in oncology[J]. Methods. 2009;48:125–38.PubMedCrossRef
16.
go back to reference Munck JN, Riggi M, Rougier P, Chabot GG, Ramirez LH, Zhao Z, et al. Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model. Cancer Res. 1993;53:1550–4.PubMed Munck JN, Riggi M, Rougier P, Chabot GG, Ramirez LH, Zhao Z, et al. Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model. Cancer Res. 1993;53:1550–4.PubMed
17.
go back to reference Guo WH, Xiong YQ. Comparison of pharmacokinetic characteristics of injecting hydroxycamptothecine through hepatic artery and auricular vein of rabbit. Chinese J Cancer Prev Treat. 2007;14:1368–71. Guo WH, Xiong YQ. Comparison of pharmacokinetic characteristics of injecting hydroxycamptothecine through hepatic artery and auricular vein of rabbit. Chinese J Cancer Prev Treat. 2007;14:1368–71.
18.
19.
go back to reference Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–42.PubMedCrossRef Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–42.PubMedCrossRef
20.
go back to reference Frei III E. In: Holland JF, Frei III E, editors. Cancer medicine. Philadelphia: Lea and Febiger; 1973. p. 717–30. Frei III E. In: Holland JF, Frei III E, editors. Cancer medicine. Philadelphia: Lea and Febiger; 1973. p. 717–30.
21.
go back to reference Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res. 2006;12:2563–7.PubMedCrossRef Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res. 2006;12:2563–7.PubMedCrossRef
22.
go back to reference van Malenstein H, Maleux G, Vandecaveye V, Heye S, Laleman W, van Pelt J, et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie. 2011;34:368–76.PubMedCrossRef van Malenstein H, Maleux G, Vandecaveye V, Heye S, Laleman W, van Pelt J, et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie. 2011;34:368–76.PubMedCrossRef
23.
go back to reference Kruskal JB, Hlatky L, Hahnfeldt P, Teramoto K, Stokes KR, Clouse ME. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. JVIR. 1993;4:741–7.PubMedCrossRef Kruskal JB, Hlatky L, Hahnfeldt P, Teramoto K, Stokes KR, Clouse ME. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. JVIR. 1993;4:741–7.PubMedCrossRef
Metadata
Title
Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization
Authors
Yue Wei Zhang
Jin Ao
Ying Liu
Ming Xi Qiao
Xue Ling Yang
Shun Xiong Tang
Chuang Li
Ke Xu
Publication date
01-11-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2408-9

Other articles of this Issue 11/2014

Tumor Biology 11/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine